RNA Q4 2020 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+48.2% YoY

Gross Profit

-$11M-535.8% margin

Operating Income

-$16M-760.6% margin

Net Income

-$16M-759.8% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+22.7%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$334M

Total Liabilities

$28M

Stockholders' Equity

$306M

Cash & Equivalents

$321M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+48.2%
Gross Profit	-$11M	-$4M	-173.3%
Operating Income	-$16M	-$6M	-169.4%
Net Income	-$16M	-$10M	-56.5%